title: Respiratory syncytial virus: old challenges and new approaches.
abstract: Better therapies and prevention strategies are needed to decrease the burden of acute RSV disease in all age populations worldwide. Furthermore, we can hypothesize that those improved measures also would likely have an effect on the chronic consequences of RSV infection in children and will reduce the incidence of recurrent wheezing and persistent pulmonary function abnormalities caused by RSV LRIs.
authors.affiliation: Pediatrics Department, Division of Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX 75390-9063, USA.
authors.forename: Susana
authors.initials: S
authors.lastname: Chávez-Bueno
authors.forename: Asunción
authors.initials: A
authors.lastname: Mejías
authors.forename: Hasan S
authors.initials: HS
authors.lastname: Jafri
authors.forename: Octavio
authors.initials: O
authors.lastname: Ramilo
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D000069455:Palivizumab; D010372:Pediatrics / Q000379:methods*; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000627:therapeutic use; D012136:Respiratory Syncytial Viruses / Q000472:pathogenicity; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D022261:Respiratory Syncytial Virus Vaccines; D000069455:Palivizumab